GSK to invest USD 1.2bn in infectious disease battle

The UK drugmaker has joined a string of pharmaceutical firms that are responding to a call of action concerning future drug resistance.

Photo: Daniel Karmann/AP/Ritzau Scanpix

GSK Plc plans to invest GBP 1bn (USD 1.2bn) over a decade to accelerate work on new medicines and vaccines to combat malaria, tuberculosis, HIV, neglected tropical diseases and antibiotic resistance.

The UK drugmaker said it has also formed a global health unit focused on the prevention and treatment of infectious diseases that disproportionately affect lower-income nations, an area that’s not usually profitable. The unit will have a “ring-fenced” budget, with results measured by health impact rather than financial returns, said Thomas Breuer, the company’s chief global health officer.

Already a subscriber? Log in.

Read the whole article

Get access for 14 days for free.
No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.

  • Access all locked articles
  • Receive our daily newsletters
  • Access our app
An error has occured. Please try again later.

Get full access for you and your coworkers.

Start a free company trial today

More from MedWatch

Further reading

Related articles

Latest news

See all jobs